search icon
canf-img

Can Fite Biopharma Ltd ADR, Common Stock

CANF

ASQ

$1.62

+$0.05

(3.18%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$9.88M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
57.55K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.57
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.29 L
$4.69 H
$1.62

About Can Fite Biopharma Ltd ADR, Common Stock

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCANFSectorS&P500
1-Week Return-2.41%0.31%-1.26%
1-Month Return7.28%0.6%-4.16%
3-Month Return-35.71%-9.44%-0.46%
6-Month Return-51.93%-5.15%3.58%
1-Year Return-18.59%0.33%22.47%
3-Year Return-87.63%4.53%25.13%
5-Year Return-93.96%35.98%77.7%
10-Year Return-99.71%100.72%190.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue2.03M763.00K853.00K810.00K743.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":37.55,"profit":true},{"date":"2021-12-31","value":41.98,"profit":true},{"date":"2022-12-31","value":39.86,"profit":true},{"date":"2023-12-31","value":36.56,"profit":true}]
Cost of Revenue51.00K---15.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":29.41,"profit":true}]
Gross Profit2.03M763.00K853.00K810.00K743.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":37.55,"profit":true},{"date":"2021-12-31","value":41.98,"profit":true},{"date":"2022-12-31","value":39.86,"profit":true},{"date":"2023-12-31","value":36.56,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses14.04M14.90M13.70M10.91M8.94M[{"date":"2019-12-31","value":94.21,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":91.9,"profit":true},{"date":"2022-12-31","value":73.18,"profit":true},{"date":"2023-12-31","value":59.98,"profit":true}]
Operating Income(12.01M)(14.14M)(12.84M)(10.10M)(8.20M)[{"date":"2019-12-31","value":-1200700000,"profit":false},{"date":"2020-12-31","value":-1413900000,"profit":false},{"date":"2021-12-31","value":-1284200000,"profit":false},{"date":"2022-12-31","value":-1009600000,"profit":false},{"date":"2023-12-31","value":-819500000,"profit":false}]
Total Non-Operating Income/Expense(1.00M)(646.00K)229.00K(154.00K)1.29M[{"date":"2019-12-31","value":-77.86,"profit":false},{"date":"2020-12-31","value":-50.19,"profit":false},{"date":"2021-12-31","value":17.79,"profit":true},{"date":"2022-12-31","value":-11.97,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(12.63M)(14.44M)(12.62M)(10.17M)(7.63M)[{"date":"2019-12-31","value":-1262500000,"profit":false},{"date":"2020-12-31","value":-1444300000,"profit":false},{"date":"2021-12-31","value":-1261500000,"profit":false},{"date":"2022-12-31","value":-1017300000,"profit":false},{"date":"2023-12-31","value":-763400000,"profit":false}]
Income Taxes427.00K363.00K(20.00K)63.00K1.00[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":85.01,"profit":true},{"date":"2021-12-31","value":-4.68,"profit":false},{"date":"2022-12-31","value":14.75,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(13.05M)(14.81M)(12.60M)(10.24M)(7.63M)[{"date":"2019-12-31","value":-1305200000,"profit":false},{"date":"2020-12-31","value":-1480600000,"profit":false},{"date":"2021-12-31","value":-1259500000,"profit":false},{"date":"2022-12-31","value":-1023600000,"profit":false},{"date":"2023-12-31","value":-763400100,"profit":false}]
Income From Continuous Operations(9.59M)(14.44M)(12.62M)(10.17M)(9.00M)[{"date":"2019-12-31","value":-958700000,"profit":false},{"date":"2020-12-31","value":-1444300000,"profit":false},{"date":"2021-12-31","value":-1261500000,"profit":false},{"date":"2022-12-31","value":-1017300000,"profit":false},{"date":"2023-12-31","value":-900100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(13.05M)(14.44M)(12.60M)(10.24M)(7.63M)[{"date":"2019-12-31","value":-1305200000,"profit":false},{"date":"2020-12-31","value":-1444300000,"profit":false},{"date":"2021-12-31","value":-1259500000,"profit":false},{"date":"2022-12-31","value":-1023600000,"profit":false},{"date":"2023-12-31","value":-763400000,"profit":false}]
EPS (Diluted)(45.50)(17.40)(8.00)(3.71)(3.00)[{"date":"2019-12-31","value":-4549.55,"profit":false},{"date":"2020-12-31","value":-1740,"profit":false},{"date":"2021-12-31","value":-800,"profit":false},{"date":"2022-12-31","value":-371.03,"profit":false},{"date":"2023-12-31","value":-300,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CANF
Cash Ratio 2.38
Current Ratio 2.93

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CANF
ROA (LTM) -57.46%
ROE (LTM) -157.62%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CANF
Debt Ratio Lower is generally better. Negative is bad. 0.58
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.42

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CANF
Trailing PE NM
Forward PE 2.97
P/S (TTM) 14.81
P/B 3.86
Price/FCF NM
EV/R 7.12
EV/Ebitda 0.10
PEG NM

FAQs

What is Can Fite Biopharma Ltd ADR share price today?

Can Fite Biopharma Ltd ADR (CANF) share price today is $1.62

Can Indians buy Can Fite Biopharma Ltd ADR shares?

Yes, Indians can buy shares of Can Fite Biopharma Ltd ADR (CANF) on Vested. To buy Can Fite Biopharma Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CANF stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Can Fite Biopharma Ltd ADR be purchased?

Yes, you can purchase fractional shares of Can Fite Biopharma Ltd ADR (CANF) via the Vested app. You can start investing in Can Fite Biopharma Ltd ADR (CANF) with a minimum investment of $1.

How to invest in Can Fite Biopharma Ltd ADR shares from India?

You can invest in shares of Can Fite Biopharma Ltd ADR (CANF) via Vested in three simple steps:

  • Click on Sign Up or Invest in CANF stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Can Fite Biopharma Ltd ADR shares
What is Can Fite Biopharma Ltd ADR 52-week high and low stock price?

The 52-week high price of Can Fite Biopharma Ltd ADR (CANF) is $4.69. The 52-week low price of Can Fite Biopharma Ltd ADR (CANF) is $1.29.

What is Can Fite Biopharma Ltd ADR price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Can Fite Biopharma Ltd ADR (CANF) is

What is Can Fite Biopharma Ltd ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Can Fite Biopharma Ltd ADR (CANF) is 3.86

What is Can Fite Biopharma Ltd ADR dividend yield?

The dividend yield of Can Fite Biopharma Ltd ADR (CANF) is 0.00%

What is the Market Cap of Can Fite Biopharma Ltd ADR?

The market capitalization of Can Fite Biopharma Ltd ADR (CANF) is $9.88M

What is Can Fite Biopharma Ltd ADR’s stock symbol?

The stock symbol (or ticker) of Can Fite Biopharma Ltd ADR is CANF

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top